Cancer Medicines: What Is Essential and Affordable in India?


Journal

JCO global oncology
ISSN: 2687-8941
Titre abrégé: JCO Glob Oncol
Pays: United States
ID NLM: 101760170

Informations de publication

Date de publication:
07 2022
Historique:
entrez: 19 7 2022
pubmed: 20 7 2022
medline: 22 7 2022
Statut: ppublish

Résumé

The WHO essential medicines list (EML) guides selection of drugs for national formularies. Here, we evaluate which medicines are considered highest priority by Indian oncologists and the extent to which they are available in routine practice. This is a secondary analysis of an electronic survey developed by the WHO EML Cancer Medicine Working Group. The survey was distributed globally using a hierarchical snowball method to physicians who prescribe systemic anticancer therapy. The survey captured the 10 medicines oncologists considered highest priority for population health and their availability in routine practice. The global study cohort included 948 respondents from 82 countries; 98 were from India and 67 were from other low- and middle-income countries. Compared with other low- and middle-income countries, the Indian cohort was more likely to be medical oncologist (70% Most high-priority cancer medicines identified by Indian oncologists are generic chemotherapy agents that provide substantial improvements in survival and are already included in WHO EML. Access to these treatments remains limited by major financial burdens experienced by patients. This is particularly acute within the private health system. Strategies are urgently needed to ensure that high-quality cancer care is affordable and accessible to all patients in India.

Identifiants

pubmed: 35853192
doi: 10.1200/GO.22.00060
pmc: PMC9812506
doi:

Substances chimiques

Antineoplastic Agents 0
Drugs, Essential 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

e2200060

Subventions

Organisme : World Health Organization
ID : 001
Pays : International
Organisme : Medical Research Council
ID : MR/W023903/1
Pays : United Kingdom

Références

PLoS One. 2018 Feb 26;13(2):e0193320
pubmed: 29481563
JCO Glob Oncol. 2020 Jul;6:1063-1075
pubmed: 32673076
Value Health. 2019 May;22(5):593-600
pubmed: 31104740
J Glob Oncol. 2018 Sep;(4):1-11
pubmed: 29244632
Lancet Oncol. 2014 May;15(6):e205-12
pubmed: 24731885
Front Pharmacol. 2013 May 07;4:57
pubmed: 23675348
ESMO Open. 2021 Jun;6(3):100166
pubmed: 34087744
Lancet Oncol. 2017 Jul;18(7):887-894
pubmed: 28583794
JAMA Oncol. 2021 May 01;7(5):728-734
pubmed: 33764385
Ann Oncol. 2016 Aug;27(8):1423-43
pubmed: 27457309
J Oncol Pract. 2018 May;14(5):e280-e294
pubmed: 29601250
Int J Equity Health. 2018 May 31;17(1):69
pubmed: 29855334
N Engl J Med. 2020 Jan 2;382(1):41-50
pubmed: 31751012
Lancet Oncol. 2021 Dec;22(12):e541-e549
pubmed: 34856151
Curr Oncol. 2019 Apr;26(2):89-93
pubmed: 31043808
Lancet Oncol. 2019 Jun;20(6):757-758
pubmed: 31162087
Lancet Oncol. 2021 Oct;22(10):1367-1377
pubmed: 34560006
Lancet Oncol. 2014 May;15(6):e223-33
pubmed: 24731888
Health Policy. 2007 Oct;83(2-3):304-13
pubmed: 17379351

Auteurs

Manju Sengar (M)

Department of Medical Oncology, Tata Memorial Centre, Homi Bhabha National Institute, Mumbai, India.

Adam Fundytus (A)

Division of Cancer Care and Epidemiology, Queen's University Cancer Research Institute, Kingston, Canada.
Department of Oncology, Queen's University, Kingston, Canada.

Wilma Hopman (W)

Department of Public Health Sciences, Queen's University, Kingston, Canada.

C S Pramesh (CS)

Department of Surgical Oncology, Tata Memorial Centre, Homi Bhabha National Institute, Mumbai, India.

Venkatraman Radhakrishnan (V)

Department of Medical Oncology, Cancer Institute (W.I.A.), Chennai, India.

Prasanth Ganesan (P)

Department of Medical Oncology, Jawaharlal Institute of Postgraduate Medical Education and Research, Puducherry, India.

Aju Mathew (A)

Malankara Orthodox Syrian Church Medical College, Kolenchery, India.

Dorothy Lombe (D)

Cancer Diseases Hospital, Lusaka, Zambia.

Matthew Jalink (M)

Division of Cancer Care and Epidemiology, Queen's University Cancer Research Institute, Kingston, Canada.
Department of Public Health Sciences, Queen's University, Kingston, Canada.

Bishal Gyawali (B)

Division of Cancer Care and Epidemiology, Queen's University Cancer Research Institute, Kingston, Canada.
Department of Oncology, Queen's University, Kingston, Canada.
Department of Public Health Sciences, Queen's University, Kingston, Canada.

Dario Trapani (D)

Division of Early Drug Development for Innovative Therapies, European Institute of Oncology IRCCS, Milan, Italy.

Felipe Roitberg (F)

Department of Noncommunicable Diseases, World Health Organization, Geneva, Switzerland.

Elisabeth G E De Vries (EGE)

Department of Medical Oncology, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands.

Lorenzo Moja (L)

Department of Health Products Policy and Standards, World Health Organization, Geneva, Switzerland.

André Ilbawi (A)

Department of Health Products Policy and Standards, World Health Organization, Geneva, Switzerland.

Richard Sullivan (R)

Institute of Cancer Policy, King's College London, London, United Kingdom.

Christopher M Booth (CM)

Division of Cancer Care and Epidemiology, Queen's University Cancer Research Institute, Kingston, Canada.
Department of Oncology, Queen's University, Kingston, Canada.
Department of Public Health Sciences, Queen's University, Kingston, Canada.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH